Acetylfentanyl    B-Anesthetic102710766

In    O
June    O
2013    O
,    O
the    O
United    O
States    O
Centers    O
for    O
Disease    O
Control    O
and    O
Prevention    O
(    O
CDC    O
)    O
issued    O
a    O
health    O
advisory    O
to    O
emergency    O
departments    O
alerting    O
to    O
14    O
overdose    O
deaths    O
among    O
intravenous    O
drug    O
users    O
in    O
Rhode    O
Island    O
associated    O
with    O
acetylfentanyl    B-Anesthetic102710766
,    O
a    O
synthetic    O
opioid    O
analog    O
of    O
fentanyl    O
that    O
has    O
never    O
been    O
licensed    O
for    O
medical    O
use    O
.    O

:    O
J01MB08    O
Nemonoxacin    B-Anesthetic102710766

Lidocaine/prilocaine    B-Anesthetic102710766
(    O
EMLA    O
,    O
eutectic    O
mixture    O
of    O
local    O
anesthetic    O
)    O

Emla    B-Anesthetic102710766

:    O
N01BB05    O
Butanilicaine    B-Anesthetic102710766

This    O
process    O
is    O
more    O
generally    O
known    O
as    O
a    O
vinylcyclopropane    B-Anesthetic102710766
rearrangement    I-Anesthetic102710766
.    O

Mebocaina    B-Anesthetic102710766
is    O
a    O
medicine    O
produced    O
by    O
Novartis    O
against    O
sore    O
throat    O
and    O
infections    O
of    O
the    O
mouth    O
and    O
the    O
pharynx    O
.    O

:    O
N01AG01    O
Narcobarbital    B-Anesthetic102710766

danofloxacin    B-Anesthetic102710766
(    O
INN    O
)    O

Decamethonium    B-Anesthetic102710766

Examples    O
include    O
the    O
nicotinic    O
agonists    O
suxamethonium    O
and    O
decamethonium    B-Anesthetic102710766
.    O

Dibucaine    B-Anesthetic102710766
number    I-Anesthetic102710766

hepatitis    O
C    O
genotype    O
I    O
virus    O
—    O
can    O
be    O
treated    O
with    O
a    O
60    O
-    O
80%    O
success    O
rate    O
with    O
the    O
current    O
standard    O
-    O
of    O
-    O
care    O
treatment    O
of    O
interferon-α    O
,    O
ribavirin    O
and    O
recently    O
approved    O
protease    O
inhibitors    O
such    O
as    O
Telaprevir    B-Anesthetic102710766
(    O
Incivek    O
)    O
May    O
2011    O
,    O
Boceprevir    B-Anesthetic102710766
(    O
Victrelis    O
)    O
May    O
2011    O
or    O
the    O
nucleotide    O
analog    O
polymerase    O
inhibitor    O
Sofosbuvir    O
(    O
Sovaldi    O
)    O
December    O
2013    O
.    O

Interferon    O
-    O
containing    O
regimens    O
may    O
also    O
include    O
protease    O
inhibitors    O
such    O
as    O
boceprevir    B-Anesthetic102710766
and    O
telaprevir    B-Anesthetic102710766
.    O

The    O
Analgizer    O
inhaler    O
was    O
withdrawn    O
in    O
1974    O
,    O
but    O
use    O
of    O
methoxyflurane    O
as    O
a    O
sedative    O
and    O
analgesic    O
continues    O
in    O
Australia    O
and    O
New    O
Zealand    O
in    O
the    O
form    O
of    O
the    O
Penthrox    B-Anesthetic102710766
inhaler    I-Anesthetic102710766
.    O

Orbifloxacin    B-Anesthetic102710766
(    O
brand    O
name    O
Orbax    B-Anesthetic102710766
)    O
is    O
a    O
fluoroquinolone    O
antibiotic    O
which    O
is    O
approved    O
for    O
use    O
in    O
dogs    O
,    O
marketed    O
by    O
Schering    O
-    O
Plough    O
Animal    O
Health    O
.    O

Rodent    B-Anesthetic102710766
cocktail    I-Anesthetic102710766
is    O
an    O
anesthetic    O
mixture    O
used    O
for    O
rodents    O
in    O
research    O
.    O

Hexylresorcinol    B-Anesthetic102710766
,    O
effective    O
in    O
single    O
dose    O

Hexylresorcinol    B-Anesthetic102710766
is    O
an    O
organic    O
compound    O
with    O
local    O
anaesthetic    O
,    O
antiseptic    O
and    O
anthelmintic    O
properties    O
.    O

garenoxacin    B-Anesthetic102710766
(    O
INN    O
)    O

Pethidinic    O
acid    O
(    O
meperidinic    O
acid    O
,    O
pethidine    O
intermediate    O
C    O
)    O
is    O
a    O
4-phenylpiperidine    O
derivative    O
that    O
is    O
both    O
a    O
metabolite    O
of    O
and    O
a    O
precursor    O
to    O
pethidine    B-Anesthetic102710766
(    O
meperidine    O
)    O
.    O

Benzethidine    O
is    O
a    O
4-phenylpiperidine    O
derivative    O
that    O
is    O
related    O
to    O
the    O
opioid    O
analgesic    O
drug    O
pethidine    B-Anesthetic102710766
(    O
"    O
meperidine    O
"    O
,    O
or    O
"    O
Demerol    O
"    O
)    O
.    O

Etoxeridine    O
(    O
Carbetidine    O
,    O
Atenos    O
)    O
is    O
a    O
4-phenylpiperidine    O
derivative    O
that    O
is    O
related    O
to    O
the    O
opioid    O
analgesic    O
drug    O
pethidine    B-Anesthetic102710766
(    O
meperidine    O
)    O
.    O

Furethidine    O
is    O
a    O
4-phenylpiperidine    O
derivative    O
that    O
is    O
related    O
to    O
the    O
opioid    O
analgesic    O
drug    O
pethidine    B-Anesthetic102710766
(    O
meperidine    O
)    O
.    O

Morpheridine    O
(    O
Morpholinoethylnorpethidine    O
)    O
is    O
a    O
4-phenylpiperidine    O
derivative    O
that    O
is    O
related    O
to    O
the    O
opioid    O
analgesic    O
drug    O
pethidine    B-Anesthetic102710766
(    O
meperidine    O
)    O
.    O

The    O
key    O
intermediate    O
,    O
normeperidine    B-Anesthetic102710766
,    O
is    O
obtained    O
by    O
a    O
scheme    O
closely    O
akin    O
to    O
the    O
parent    O
molecule    O
.    O

Pheneridine    O
is    O
a    O
4-Phenylpiperidine    O
derivative    O
that    O
is    O
related    O
to    O
the    O
opioid    O
analgesic    O
drug    O
pethidine    B-Anesthetic102710766
(    O
meperidine    O
)    O
.    O

Oxpheneridine    O
(    O
Carbamethidine    O
)    O
is    O
a    O
4-phenylpiperidine    O
derivative    O
that    O
is    O
related    O
to    O
the    O
opioid    O
analgesic    O
drug    O
pethidine    B-Anesthetic102710766
(    O
meperidine    O
)    O
.    O

Sameridine    O
is    O
a    O
4-phenylpiperidine    O
derivative    O
that    O
is    O
related    O
to    O
the    O
opioid    O
analgesic    O
drug    O
pethidine    B-Anesthetic102710766
(    O
meperidine    O
)    O
.    O

PEPAP    O
(    O
Phenethylphenylacetoxypiperidine    O
)    O
is    O
an    O
opioid    O
analgesic    O
that    O
is    O
an    O
analog    O
of    O
pethidine    B-Anesthetic102710766
(    O
meperidine    O
)    O
.    O

Pethidine    O
intermediate    O
A    O
is    O
a    O
4-phenylpiperidine    O
derivative    O
that    O
is    O
a    O
precursor    O
to    O
the    O
opioid    O
analgesic    O
drug    O
pethidine    B-Anesthetic102710766
(    O
meperidine    O
)    O
.    O

However    O
,    O
it    O
is    O
noted    O
that    O
opioid    O
/    O
antihistamine    O
combinations    O
are    O
used    O
clinically    O
for    O
their    O
synergistic    O
effect    O
in    O
the    O
management    O
of    O
pain    O
and    O
maintenance    O
of    O
dissociative    O
anesthesia    O
(    O
sedation    O
)    O
in    O
such    O
preparations    O
as    O
Meprozine    B-Anesthetic102710766
(    O
meperidine    B-Anesthetic102710766
/    O
promethazine    O
)    O
and    O
Diconal    O
(    O
dipipanone    O
/    O
cyclizine    O
)    O
,    O
which    O
act    O
as    O
strong    O
anticholinergic    O
agents    O
.    O

(    O
e    O
)    O
any    O
compound    O
(    O
not    O
being    O
a    O
compound    O
for    O
the    O
time    O
being    O
specified    O
in    O
sub    O
-    O
paragraph    O
(    O
a    O
)    O
above    O
)    O
structurally    O
derived    O
from    O
pethidine    B-Anesthetic102710766
by    O
modification    O
in    O
any    O
of    O
the    O
following    O
ways    O
,    O
that    O
is    O
to    O
say    O
,    O

It    O
was    O
discovered    O
by    O
Hoffman    O
-    O
La    O
Roche    O
in    O
1957    O
during    O
research    O
into    O
the    O
related    O
drug    O
pethidine    B-Anesthetic102710766
.    O

It    O
was    O
developed    O
in    O
the    O
early    O
1950s    O
in    O
the    O
USSR    O
during    O
research    O
into    O
the    O
related    O
drug    O
pethidine    B-Anesthetic102710766
.    O

It    O
was    O
further    O
developed    O
in    O
Russia    O
in    O
the    O
1990s    O
during    O
research    O
into    O
the    O
related    O
drug    O
pethidine    B-Anesthetic102710766
.    O

Meprodine    O
is    O
an    O
opioid    O
analgesic    O
that    O
is    O
an    O
analogue    O
of    O
pethidine    B-Anesthetic102710766
(    O
meperidine    O
)    O
.    O

Piminodine    O
(    O
Alvodine    O
)    O
is    O
an    O
opioid    O
analgesic    O
that    O
is    O
an    O
analogue    O
of    O
pethidine    B-Anesthetic102710766
(    O
meperidine    O
)    O
.    O

In    O
many    O
patients    O
,    O
propiram    O
is    O
an    O
effective    O
analgesic    O
comparable    O
to    O
other    O
drugs    O
such    O
as    O
these    O
as    O
well    O
as    O
pethidine    B-Anesthetic102710766
,    O
with    O
a    O
normal    O
dose    O
of    O
around    O
50–100    O
mg    O
and    O
a    O
duration    O
of    O
action    O
of    O
3    O
to    O
6    O
hours    O
.    O

It    O
was    O
invented    O
in    O
the    O
1950s    O
and    O
is    O
related    O
to    O
other    O
drugs    O
such    O
as    O
proheptazine    O
and    O
pethidine    B-Anesthetic102710766
.    O

Morphine    O
,    O
the    O
archetypal    O
opioid    O
,    O
and    O
other    O
opioids    O
(    O
e.g.    O
,    O
codeine    O
,    O
oxycodone    O
,    O
hydrocodone    O
,    O
dihydromorphine    O
,    O
pethidine    B-Anesthetic102710766
)    O
all    O
exert    O
a    O
similar    O
influence    O
on    O
the    O
cerebral    O
opioid    O
receptor    O
system    O
.    O

Additionally    O
,    O
IV    O
sedation    O
is    O
frequently    O
administered    O
as    O
a    O
concoction    O
of    O
several    O
agents    O
including    O
those    O
previously    O
mentioned    O
for    O
induction    O
and    O
maintenance    O
of    O
anesthesia    O
,    O
as    O
well    O
as    O
a    O
benzodiazepine    O
(    O
usually    O
midazolam    O
,    O
but    O
temazepam    O
or    O
flunitrazepam    O
are    O
also    O
used    O
via    O
the    O
oral    O
route    O
)    O
and    O
a    O
narcotic    O
/    O
systemic    O
analgesic    O
such    O
as    O
demerol    B-Anesthetic102710766
or    O
fentanyl    O
.    O

In    O
1999    O
he    O
suffered    O
a    O
knee    O
injury    O
and    O
was    O
drug    O
tested    O
the    O
day    O
after    O
surgery    O
,    O
returning    O
a    O
positive    O
test    O
for    O
pethidine    B-Anesthetic102710766
,    O
a    O
banned    O
substance    O
.    O

levobupivacaine    B-Anesthetic102710766

Ted    O
takes    O
him    O
home    O
,    O
and    O
Blake    O
gets    O
him    O
to    O
try    O
GHB    B-Anesthetic102710766
,    O
with    O
disastrous    O
results    O
.    O

GMHC    O
pulled    O
the    O
plug    O
after    O
the    O
1998    O
fundraiser    O
after    O
one    O
man    O
died    O
on    O
Fire    O
Island    O
of    O
an    O
overdose    O
of    O
the    O
drug    O
gamma    B-Anesthetic102710766
hydroxy    I-Anesthetic102710766
butyrate    I-Anesthetic102710766
(    O
GHB    O
)    O
the    O
evening    O
before    O
the    O
party    O
and    O
21    O
revelers    O
were    O
arrested    O
for    O
drug    O
possession    O
.    O

The    O
controlled    O
drug    O
which    O
it    O
was    O
alleged    O
1,4-B    O
was    O
substantially    O
similar    O
to    O
was    O
gamma-hydroxybutyrate    B-Anesthetic102710766
(    O
GHB    O
)    O
.    O

Substances    O
that    O
may    O
cause    O
this    O
toxidrome    O
include    O
anticonvulsants    O
,    O
barbiturates    O
,    O
benzodiazepines    O
,    O
gamma-Hydroxybutyric    B-Anesthetic102710766
acid    I-Anesthetic102710766
,    O
Methaqualone    O
,    O
and    O
ethanol    O
.    O

gamma-hydroxybutyric    B-Anesthetic102710766
acid    I-Anesthetic102710766
(    O
GHB    O
)    O

David    O
Amess    O
,    O
the    O
Conservative    O
Member    O
of    O
Parliament    O
for    O
Basildon    O
,    O
was    O
fooled    O
into    O
filming    O
an    O
elaborate    O
video    O
warning    O
against    O
the    O
dangers    O
of    O
this    O
drug    O
,    O
and    O
went    O
as    O
far    O
as    O
to    O
ask    O
a    O
question    O
about    O
"    O
Cake    O
"    O
in    O
the    O
UK    O
Parliament    O
,    O
alongside    O
real    O
substances    O
khat    O
and    O
gamma-hydroxybutyric    B-Anesthetic102710766
acid    I-Anesthetic102710766
.    O

Valeric    O
acid    O
appears    O
similar    O
in    O
structure    O
to    O
GHB    B-Anesthetic102710766
and    O
the    O
neurotransmitter    O
GABA    O
in    O
that    O
it    O
is    O
a    O
short    O
-    O
chain    O
carboxylic    O
acid    O
,    O
although    O
it    O
lacks    O
the    O
alcohol    O
and    O
amine    O
functional    O
groups    O
that    O
contribute    O
to    O
the    O
biological    O
activities    O
of    O
GHB    O
and    O
GABA    O
,    O
respectively    O
.    O

The    O
medical    O
examiner    O
stated    O
that    O
Tang    O
was    O
found    O
with    O
320    O
wounds    O
from    O
blunt    O
force    O
trauma    O
(    O
not    O
including    O
bruises    O
)    O
and    O
with    O
high    O
doses    O
of    O
the    O
drug    O
GHB    B-Anesthetic102710766
in    O
her    O
system    O
,    O
together    O
with    O
trace    O
amounts    O
of    O
cocaine    O
.    O

The    O
Emergency    O
Department    O
was    O
one    O
of    O
the    O
first    O
in    O
NSW    O
to    O
implement    O
a    O
PECC    O
(    O
Psychiatric    O
Emergency    O
Care    O
Centre    O
)    O
,    O
in    O
response    O
to    O
the    O
high    O
number    O
of    O
people    O
with    O
a    O
mental    O
illness    O
residing    O
in    O
the    O
inner    O
suburbs    O
of    O
Sydney    O
,    O
as    O
well    O
as    O
the    O
increasing    O
incidence    O
of    O
people    O
affected    O
by    O
illegal    O
,    O
psychoactive    O
drugs    O
such    O
as    O
heroin    O
,    O
GHB    B-Anesthetic102710766
and    O
crystal    O
meth    O
.    O

4-Hydroxy-4-methylpentanoic    O
acid    O
(    O
UMB68    O
)    O
is    O
a    O
tertiary    O
alcohol    O
,    O
similar    O
in    O
structure    O
to    O
the    O
drug    O
GHB    B-Anesthetic102710766
.    O

The    O
chemical    O
gamma-hydroxybutyric    B-Anesthetic102710766
acid    I-Anesthetic102710766
(    O
GHB    O
)    O
has    O
been    O
studied    O
to    O
increase    O
SWS    O
.    O

GHB    B-Anesthetic102710766

This    O
includes    O
drugs    O
less    O
immediately    O
classed    O
to    O
a    O
slowing    O
of    O
the    O
metabolism    O
such    O
as    O
with    O
GABAergics    O
like    O
GHB    B-Anesthetic102710766
or    O
glutamatergic    O
antagonists    O
like    O
PCP    O
or    O
ketamine    O
.    O

For    O
instance    O
,    O
GHB    B-Anesthetic102710766
,    O
a    O
naturally    O
occurring    O
substance    O
in    O
the    O
central    O
nervous    O
system    O
is    O
considered    O
a    O
drug    O
,    O
and    O
is    O
illegal    O
in    O
many    O
countries    O
,    O
while    O
nicotine    O
is    O
not    O
officially    O
considered    O
a    O
drug    O
in    O
most    O
countries    O
.    O

Benjie    O
breaks    O
his    O
sobriety    O
,    O
getting    O
high    O
on    O
GHB    B-Anesthetic102710766
,    O
and    O
carelessly    O
shoots    O
the    O
dog    O
of    O
his    O
only    O
friend    O
.    O

Also    O
recovered    O
in    O
the    O
operation    O
were    O
synthetic    O
materials    O
,    O
various    O
drug    O
paraphernalia    O
and    O
a    O
manual    O
on    O
making    O
illegal    O
drugs    O
such    O
as    O
methamphetamine    O
hydrochloride    O
or    O
shabu    O
,    O
D    O
-    O
lysergic    O
acid    O
diethylamide    O
and    O
gamma-Hydroxybutyric    B-Anesthetic102710766
acid    I-Anesthetic102710766
(    O
GHB    O
)    O
or    O
liquid    O
ecstasy    O
.    O

γ-Hydroxybutyraldehyde    O
,    O
also    O
referred    O
to    O
as    O
GHBAL    O
,    O
γ-hydroxybutaldehyde    O
or    O
γ-hydroxybutanal    O
,    O
is    O
a    O
chemical    O
intermediate    O
in    O
the    O
biosynthesis    O
of    O
the    O
neurotransmitter    O
γ-hydroxybutyric    B-Anesthetic102710766
acid    I-Anesthetic102710766
(    O
GHB    O
)    O
from    O
1,4-butanediol    O
(    O
1,4-BD    O
)    O
.    O

After    O
sleeping    O
with    O
JJ    O
,    O
Theresa    O
overdoses    O
on    O
marijuana    O
and    O
GHB    B-Anesthetic102710766
.    O

John    O
follows    O
Hector    O
deeper    O
into    O
circuit    O
scene    O
,    O
using    O
a    O
variety    O
of    O
drugs    O
including    O
Special    O
K    O
,    O
GHB    B-Anesthetic102710766
,    O
cocaine    O
,    O
crystal    O
meth    O
and    O
,    O
suffering    O
from    O
body    O
dysmorphia    O
despite    O
being    O
in    O
terrific    O
physical    O
shape    O
,    O
anabolic    O
steroids    O
.    O

A    O
toxicology    O
report    O
revealed    O
20    O
mg    O
/    O
mL    O
of    O
GHB    B-Anesthetic102710766
in    O
his    O
system    O
,    O
which    O
the    O
coroner    O
said    O
did    O
not    O
contribute    O
to    O
Barrier    O
's    O
death    O
.    O

It    O
also    O
directed    O
the    O
United    O
States    O
Sentencing    O
Commission    O
to    O
consider    O
increasing    O
federal    O
sentencing    O
penalties    O
for    O
offenses    O
involving    O
gamma-Hydroxybutyric    B-Anesthetic102710766
acid    I-Anesthetic102710766
(    O
GHB    O
)    O
.    O

foretinib    B-Anesthetic102710766
(    O
USAN    O
,    O
INN    O
)    O

VX-680    B-Anesthetic102710766
is    O
an    O
aurora    O
inhibitor    O
.    O

Balofloxacin    B-Anesthetic102710766
is    O
an    O
orally    O
active    O
fluoroquinolone    O
antibiotic    O
developed    O
by    O
Choongwae    O
Pharma    O
for    O
the    O
treatment    O
of    O
urinary    O
tract    O
infections    O
.    O

Equithesin    B-Anesthetic102710766
-    O
a    O
general    O
anesthetic    O
agent    O
containing    O
chloral    O
hydrate    O
,    O
magnesium    O
sulfate    O
and    O
pentobarbital    O

Simeprevir    B-Anesthetic102710766
,    O
sold    O
under    O
the    O
trade    O
names    O
Olysio    B-Anesthetic102710766
among    O
others    O
,    O
is    O
a    O
medication    O
used    O
in    O
combination    O
with    O
other    O
medications    O
for    O
the    O
treatment    O
of    O
hepatitis    O
C.    O
It    O
is    O
specifically    O
used    O
for    O
hepatitis    O
C    O
genotype    O
1    O
and    O
4    O
.    O

Simeprevir    B-Anesthetic102710766
(    O
TMC435    O
,    O
tradename    O
Olysio    O
)    O
,    O
an    O
HCV    O
NS3/4A    O
protease    O
inhibitor    O
for    O
treatment    O
of    O
chronic    O
hepatitis    O
C    O
in    O
combination    O
with    O
pegylated    O
interferon    O
/    O
ribavirin    O
or    O
with    O
other    O
direct    O
-    O
acting    O
anti    O
-    O
HCV    O
agents    O
.    O

PRL-8-53    B-Anesthetic102710766

brand    O
name    O
for    O
Iontocaine    B-Anesthetic102710766

It    O
's    O
also    O
contraindicated    O
if    O
patient    O
is    O
taking    O
Macrolide    O
antibiotics    O
(    O
eg    O
,    O
erythromycin    O
)    O
,    O
certain    O
HIV    O
protease    O
inhibitors    O
(    O
eg    O
,    O
ritonavir    O
,    O
nelfinavir    O
,    O
indinavir    O
)    O
,    O
certain    O
azole    O
antifungals    O
(    O
eg    O
,    O
ketoconazole    O
,    O
itraconazole    O
,    O
voriconazole    O
)    O
delavirdine    O
,    O
efavirenz    B-Anesthetic102710766
or    O
a    O
5-HT1    O
agonist    O
(    O
eg    O
,    O
sumatriptan    O
)    O
.    O

In    O
July    O
2006    O
,    O
the    O
U.S.    O
Food    O
and    O
Drug    O
Administration    O
(    O
FDA    O
)    O
approved    O
Atripla    O
,    O
a    O
once    O
a    O
day    O
single    O
tablet    O
regimen    O
for    O
HIV    O
,    O
combining    O
Sustiva    O
(    O
efavirenz    B-Anesthetic102710766
)    O
,    O
a    O
Bristol    O
-    O
Myers    O
Squibb    O
product    O
,    O
and    O
Truvada    O
(    O
emtricitabine    O
and    O
tenofovir    O
disoproxil    O
)    O
,    O
a    O
Gilead    O
product    O
.    O

's    O
patented    O
drug    O
efavirenz    B-Anesthetic102710766
,    O
also    O
because    O
of    O
an    O
urgent    O
need    O
and    O
an    O
inability    O
to    O
pay    O
for    O
the    O
drug    O
.    O

Efavirenz    B-Anesthetic102710766
has    O
the    O
trade    O
names    O
Sustiva    O
and    O
Stocrin    O
.    O

Examples    O
of    O
drugs    O
commonly    O
associated    O
with    O
depressogenic    O
effects    O
include    O
some    O
anticonvulsants    O
such    O
as    O
the    O
barbiturates    O
(    O
e.g.    O
phenobarbital    O
)    O
,    O
benzodiazepines    O
(    O
e.g.    O
diazepam    O
)    O
,    O
vigabatrin    O
,    O
and    O
topiramate    O
,    O
corticosteroids    O
like    O
dexamethasone    O
and    O
prednisone    O
,    O
cytokines    O
like    O
interferon-α    O
and    O
interleukin-2    O
,    O
certain    O
antihypertensives    O
such    O
as    O
amiodarone    O
,    O
clonidine    O
,    O
methyldopa    O
,    O
reserpine    O
,    O
and    O
tetrabenazine    O
(    O
used    O
as    O
an    O
antipsychotic    O
/    O
antihyperkinetic    O
)    O
,    O
and    O
agents    O
with    O
antiandrogen    O
,    O
antiestrogen    O
,    O
and/or    O
anti    O
-    O
neurosteroid    O
activities    O
such    O
as    O
GnRH    O
agonists    O
(    O
e.g.    O
,    O
leuprolide    O
,    O
goserelin    O
)    O
,    O
anastrozole    O
(    O
an    O
aromatase    O
inhibitor    O
)    O
,    O
finasteride    O
(    O
a    O
5α-reductase    O
inhibitor    O
)    O
,    O
and    O
clomiphene    O
(    O
a    O
SERM    O
)    O
,    O
as    O
well    O
as    O
others    O
including    O
flunarizine    O
,    O
mefloquine    O
,    O
and    O
efavirenz    B-Anesthetic102710766
.    O

Some    O
notable    O
drugs    O
containing    O
trifluoromethyl    O
groups    O
include    O
efavirenz    B-Anesthetic102710766
(    O
Sustiva    O
)    O
,    O
an    O
HIV    O
reverse    O
transcriptase    O
inhibitor    O
;    O
fluoxetine    O
(    O
Prozac    O
)    O
,    O
an    O
antidepressant    O
;    O
and    O
celecoxib    O
(    O
Celebrex    O
)    O
,    O
a    O
nonsteroidal    O
anti    O
-    O
inflammatory    O
drug    O
.    O

There    O
have    O
been    O
reports    O
of    O
increased    O
liver    O
toxicity    O
in    O
people    O
with    O
HIV    O
/    O
AIDS    O
on    O
zidovudine    O
or    O
efavirenz    B-Anesthetic102710766
when    O
treated    O
with    O
amodiaquine    O
-    O
containing    O
ACT    O
regimens    O
,    O
therefore    O
it    O
is    O
recommended    O
that    O
these    O
people    O
avoid    O
amodiaquine    O
.    O

Etravirine    O
is    O
a    O
second    O
-    O
generation    O
non    O
-    O
nucleoside    O
reverse    O
transcriptase    O
inhibitor    O
(    O
NNRTI    O
)    O
,    O
designed    O
to    O
be    O
active    O
against    O
HIV    O
with    O
mutations    O
that    O
confer    O
resistance    O
to    O
the    O
two    O
most    O
commonly    O
prescribed    O
first    O
-    O
generation    O
NNRTIs    O
,    O
mutation    O
K103N    O
for    O
efavirenz    B-Anesthetic102710766
and    O
Y181C    O
for    O
nevirapine    O
.    O

hepatitis    O
C    O
genotype    O
I    O
virus    O
—    O
can    O
be    O
treated    O
with    O
a    O
60    O
-    O
80%    O
success    O
rate    O
with    O
the    O
current    O
standard    O
-    O
of    O
-    O
care    O
treatment    O
of    O
interferon-α    O
,    O
ribavirin    O
and    O
recently    O
approved    O
protease    O
inhibitors    O
such    O
as    O
Telaprevir    B-Anesthetic102710766
(    O
Incivek    O
)    O
May    O
2011    O
,    O
Boceprevir    B-Anesthetic102710766
(    O
Victrelis    O
)    O
May    O
2011    O
or    O
the    O
nucleotide    O
analog    O
polymerase    O
inhibitor    O
Sofosbuvir    O
(    O
Sovaldi    O
)    O
December    O
2013    O
.    O

Interferon    O
-    O
containing    O
regimens    O
may    O
also    O
include    O
protease    O
inhibitors    O
such    O
as    O
boceprevir    B-Anesthetic102710766
and    O
telaprevir    B-Anesthetic102710766
.    O

Ropivacaine    B-Anesthetic102710766
(    O
rINN    O
)    O
is    O
a    O
local    O
anaesthetic    O
drug    O
belonging    O
to    O
the    O
amino    O
amide    O
group    O
.    O

Ropivacaine    B-Anesthetic102710766
hydrochloride    I-Anesthetic102710766
is    O
commonly    O
marketed    O
by    O
AstraZeneca    O
under    O
the    O
trade    O
name    O
Naropin    B-Anesthetic102710766
.    O

1952    O
Howard    O
E.    O
Simmons    O
-    O
Dupont    O
chemist    O
that    O
discovered    O
the    O
Simmons–Smith    B-Anesthetic102710766
reaction    I-Anesthetic102710766

A    O
Simmons-Smith    B-Anesthetic102710766
like    O
reaction    O
with    O
an    O
alkene    O
containing    O
ring    O
can    O
be    O
used    O
to    O
introduce    O
a    O
single    O
carbon    O
.    O

One    O
reaction    O
variation    O
is    O
cyclopropanation    B-Anesthetic102710766
to    O
a    O
compound    O
class    O
called    O
"    O
ivyanes    O
"    O
with    O
a    O
reported    O
synthesis    O
in    O
a    O
Simmons–Smith    B-Anesthetic102710766
reaction    I-Anesthetic102710766
(    O
diethyl    O
zinc    O
/    O
trifluoroacetic    O
acid    O
)    O
of    O
the    O
first    O
6    O
members    O
.    O

For    O
example    O
,    O
rainbow    O
trout    O
exposed    O
to    O
two    O
narcotics    O
,    O
MS-222    B-Anesthetic102710766
and    O
1-octanol    O
exhibited    O
a    O
variety    O
of    O
respiratory    O
-    O
cardiovascular    O
responses    O
.    O

4-Fluorobutyrylfentanyl    O
(    O
also    O
known    O
as    O
4-FBF    O
and    O
p    O
-    O
FBF    O
)    O
is    O
an    O
opioid    O
analgesic    O
that    O
is    O
an    O
analog    O
of    O
butyrfentanyl    B-Anesthetic102710766
and    O
has    O
been    O
sold    O
online    O
as    O
a    O
designer    O
drug    O
.    O

Butyrfentanyl    B-Anesthetic102710766

Antagonists    O
/    O
negative    O
allosteric    O
modulators    O
:    O
bicuculline    O
,    O
cicutoxin    O
,    O
flumazenil    B-Anesthetic102710766
,    O
furosemide    O
,    O
gabazine    O
,    O
oenanthotoxin    O
,    O
picrotoxin    O
,    O
Ro15    O
-    O
4513    O
,    O
thujone    B-Anesthetic102710766
,    O
amentoflavone    O
.    O

Its    O
leaves    O
have    O
been    O
shown    O
to    O
contain    O
thujone    B-Anesthetic102710766
and    O
cineole    O
.    O

"    O
Artemisia    O
absinthium    O
"    O
contains    O
thujone    B-Anesthetic102710766
,    O
a    O
GABAA    O
receptor    O
antagonist    O
that    O
can    O
cause    O
epileptic    O
-    O
like    O
convulsions    O
and    O
kidney    O
failure    O
when    O
ingested    O
in    O
large    O
amounts    O
.    O

The    O
compound    O
shows    O
biological    O
activity    O
and    O
has    O
shown    O
promise    O
as    O
an    O
anti    O
-    O
inflammatory    O
agent    O
,    O
and    O
should    O
not    O
to    O
be    O
confused    O
with    O
thujone    B-Anesthetic102710766
,    O
a    O
neurotoxin    O
also    O
found    O
in    O
"    O
Artemisia    O
absinthium    O
"    O
.    O

It    O
has    O
been    O
suggested    O
that    O
van    O
Gogh    O
was    O
not    O
just    O
bipolar    O
,    O
but    O
that    O
the    O
crises    O
in    O
his    O
last    O
two    O
years    O
were    O
brought    O
about    O
by    O
the    O
additional    O
effect    O
of    O
thujone    B-Anesthetic102710766
poisoning    O
from    O
his    O
consumption    O
of    O
absinthe    O
.    O

Factive    B-Anesthetic102710766

Buthalital    B-Anesthetic102710766
sodium    I-Anesthetic102710766
(    O
INN    O
;    O
Bayinal    B-Anesthetic102710766
,    O
Baytinal    B-Anesthetic102710766
,    O
Thialbutal    B-Anesthetic102710766
,    O
Transithal    B-Anesthetic102710766
,    O
Ulbreval    B-Anesthetic102710766
)    O
,    O
or    O
buthalitone    B-Anesthetic102710766
sodium    I-Anesthetic102710766
(    O
BAN    O
)    O
,    O
is    O
a    O
barbiturate    O
derivative    O
which    O
was    O
under    O
development    O
as    O
a    O
short    O
-    O
acting    O
anesthetic    O
.    O

While    O
preparing    O
for    O
a    O
series    O
of    O
comeback    O
concerts    O
scheduled    O
to    O
begin    O
in    O
July    O
2009    O
,    O
Jackson    O
died    O
of    O
acute    O
propofol    B-Anesthetic102710766
and    O
benzodiazepine    O
intoxication    O
after    O
suffering    O
cardiac    O
arrest    O
on    O
June    O
25    O
,    O
2009    O
.    O

Propofol    B-Anesthetic102710766

It    O
has    O
been    O
implicated    O
in    O
addictions    O
to    O
alcohol    O
,    O
cannabinoids    O
,    O
cocaine    O
,    O
methylphenidate    O
,    O
nicotine    O
,    O
opioids    O
,    O
phencyclidine    O
,    O
propofol    B-Anesthetic102710766
,    O
and    O
substituted    O
amphetamines    O
,    O
among    O
others    O
.    O

propofol    B-Anesthetic102710766
and    O
fospropofol    B-Anesthetic102710766
(    O
anesthetics    O
)    O

It    O
has    O
a    O
faster    O
recovery    O
time    O
compared    O
to    O
midazolam    O
and    O
has    O
a    O
reduced    O
incidence    O
of    O
post    O
-    O
operative    O
excitement    O
and    O
results    O
in    O
a    O
reduction    O
in    O
dose    O
required    O
of    O
propofol    B-Anesthetic102710766
and    O
thiopental    O
.    O

In    O
2013    O
,    O
she    O
became    O
involved    O
in    O
another    O
controversy    O
when    O
she    O
was    O
indicted    O
for    O
illegal    O
use    O
of    O
the    O
drug    O
propofol    B-Anesthetic102710766
.    O

In    O
2013    O
,    O
she    O
was    O
investigated    O
then    O
indicted    O
for    O
illegal    O
use    O
of    O
the    O
narcotic    O
propofol    B-Anesthetic102710766
.    O

Propofol    B-Anesthetic102710766

In    O
some    O
cases    O
,    O
usually    O
where    O
longer    O
strictures    O
are    O
present    O
,    O
a    O
rapidly    O
metabolized    O
hypnotic    O
agent    O
such    O
as    O
propofol    B-Anesthetic102710766
may    O
be    O
selected    O
,    O
as    O
this    O
allows    O
for    O
the    O
immediate    O
induction    O
of    O
short    O
-    O
term    O
general    O
anesthesia    O
(    O
note    O
:    O
endotracheal    O
intubation    O
will    O
also    O
be    O
necessary    O
if    O
general    O
anesthesia    O
is    O
administered    O
)    O
.    O

They    O
stop    O
Ressler    O
just    O
in    O
time    O
from    O
killing    O
Hitchin    O
and    O
Liz    O
revealing    O
he    O
was    O
under    O
the    O
influence    O
of    O
propofol    B-Anesthetic102710766
and    O
manipulated    O
to    O
kill    O
Hitchin    O
by    O
Kaplan    O
and    O
Krilov    O
.    O

On    O
June    O
25    O
,    O
2009    O
,    O
only    O
weeks    O
after    O
hiring    O
Murray    O
,    O
Jackson    O
died    O
due    O
to    O
a    O
lethal    O
dose    O
of    O
propofol    B-Anesthetic102710766
.    O

The    O
anaesthetic    O
that    O
was    O
used    O
Propofol    B-Anesthetic102710766
,    O
but    O
shortly    O
after    O
the    O
anaesthetic    O
was    O
admitted    O
,    O
he    O
lost    O
consciousness    O
and    O
went    O
into    O
cardiac    O
arrest    O
.    O

Propofol    B-Anesthetic102710766

Commonly    O
used    O
hypnotics    O
include    O
thiopental    O
,    O
propofol    B-Anesthetic102710766
and    O
etomidate    O
.    O

These    O
drugs    O
can    O
be    O
administered    O
via    O
gases    O
,    O
such    O
as    O
nitrous    O
oxide    O
(    O
laughing    O
gas    O
)    O
,    O
or    O
intravenously    O
,    O
with    O
drugs    O
such    O
as    O
ketamine    O
(    O
pediatrics    O
primarily    O
,    O
and    O
infrequently    O
in    O
adults    O
)    O
,    O
propofol    B-Anesthetic102710766
,    O
and    O
midazolam    O
.    O

VandenBurg    O
advised    O
the    O
UK    O
press    O
on    O
the    O
use    O
of    O
propofol    B-Anesthetic102710766
in    O
the    O
Death    O
of    O
Michael    O
Jackson    O
.    O

gatifloxacin    B-Anesthetic102710766
(    O
Zigat    O
,    O
Tequin    O
)    O
(    O
Zymar    O
-opth    O
.    O
)    O

gatifloxacin    B-Anesthetic102710766
(    O
INN    O
)    O

firocoxib    B-Anesthetic102710766
(    O
USAN    O
)    O

clinafloxacin    B-Anesthetic102710766

A-834,735    B-Anesthetic102710766

A-834,735    B-Anesthetic102710766

Also    O
see    O
the    O
divinylcyclopropane-cycloheptadiene    B-Anesthetic102710766
rearrangement    I-Anesthetic102710766
.    O

Procinolol    B-Anesthetic102710766

Polidocanol    B-Anesthetic102710766
is    O
a    O
local    O
anaesthetic    O
and    O
antipruritic    O
component    O
of    O
ointments    O
and    O
bath    O
additives    O
.    O

mepivacaine    B-Anesthetic102710766
(    O
INN    O
)    O

Lidocaine    B-Anesthetic102710766
,    O
mepivacaine    B-Anesthetic102710766
,    O
and    O
bupivacaine    B-Anesthetic102710766
are    O
the    O
most    O
commonly    O
used    O
local    O
anesthetics    O
used    O
in    O
veterinary    O
medicine    O
.    O

mepivacaine    B-Anesthetic102710766

Burow's    B-Anesthetic102710766
solution    I-Anesthetic102710766
,    O
an    O
astringent    O
aqueous    O
solution    O
of    O
aluminium    O
acetate    O
,    O
is    O
shown    O
to    O
soothe    O
and    O
to    O
relieve    O
itching    O
.    O

Burow's    B-Anesthetic102710766
solution    I-Anesthetic102710766
is    O
a    O
preparation    O
of    O
aluminium    O
subacetate    O
and    O
glacial    O
acetic    O
acid    O
.    O

They    O
are    O
part    O
of    O
the    O
group    O
of    O
saxitoxins    O
,    O
a    O
large    O
group    O
of    O
neurotoxins    O
along    O
with    O
a    O
molecule    O
that    O
is    O
also    O
referred    O
to    O
as    O
saxitoxin    O
(    O
STX    O
)    O
,    O
neosaxitoxin    B-Anesthetic102710766
(    O
NSTX    O
)    O
and    O
decarbamoylsaxitoxin    O
(    O
dcSTX    O
)    O
.    O

But    O
the    O
term    O
saxitoxin    O
can    O
also    O
refer    O
to    O
the    O
entire    O
suite    O
of    O
more    O
than    O
50    O
structurally    O
related    O
neurotoxins    O
(    O
known    O
collectively    O
as    O
"    O
saxitoxins    O
"    O
)    O
produced    O
by    O
algae    O
and    O
cyanobacteria    O
which    O
includes    O
saxitoxin    O
itself    O
(    O
STX    O
)    O
,    O
neosaxitoxin    B-Anesthetic102710766
(    O
NSTX    O
)    O
,    O
gonyautoxins    O
(    O
GTX    O
)    O
and    O
decarbamoylsaxitoxin    O
(    O
dcSTX    O
)    O
.    O

Intranasal    O
esketamine    B-Anesthetic102710766
,    O
an    O
enantiomer    O
of    O
ketamine    O
,    O
is    O
in    O
the    O
final    O
stages    O
of    O
development    O
for    O
depression    O
.    O

NMDA    O
receptor    O
antagonists    O
like    O
ketamine    O
,    O
esketamine    B-Anesthetic102710766
(    O
JNJ-54135419    O
)    O
,    O
rapastinel    O
(    O
GLYX-13    O
)    O
,    O
apimostinel    O
(    O
NRX-1074    O
)    O
,    O
4-chlorokynurenine    O
(    O
AV-101    O
)    O
,    O
traxoprodil    O
(    O
CP-101606    O
)    O
,    O
rislenemdaz    O
(    O
CERC-301    O
,    O
MK-0657    O
)    O
,    O
nitrous    O
oxide    O
,    O
and    O
others    O

ketamine    O
(    O
dissociative    O
)    O
and    O
its    O
stereoisomer    O
esketamine    B-Anesthetic102710766

It    O
is    O
similar    O
in    O
physiological    O
effect    O
but    O
different    O
in    O
composition    O
to    O
the    O
now    O
withdrawn    O
Saffan    B-Anesthetic102710766
.    O

Amino    B-Anesthetic102710766
esters    I-Anesthetic102710766
are    O
a    O
class    O
of    O
local    O
anesthetics    O
.    O

FUB-144    O
—    O
the    O
"    O
N"-(4-fluorobenzyl    O
)    O
analogue    O
of    O
UR-144    B-Anesthetic102710766
and    O
XLR-11    O
.    O

XLR-11    O
—    O
the    O
terminally    O
fluorinated    O
(    O
5-fluoro    O
)    O
analogue    O
of    O
UR-144    B-Anesthetic102710766
.    O

XLR-12    O
—    O
the    O
terminally    O
trifluorinated    O
(    O
4,4,4-trifluorobutyl    O
)    O
analogue    O
of    O
UR-144    B-Anesthetic102710766
.    O

4'-Fluorococaine    B-Anesthetic102710766

TEAL    O
can    O
also    O
be    O
generated    O
from    O
ethylaluminium    O
sesquichloride    O
(    O
Al2Cl3Et3    O
)    O
,    O
which    O
arises    O
by    O
treating    O
aluminium    O
powder    O
with    O
chloroethane    B-Anesthetic102710766
.    O

It    O
can    O
be    O
prepared    O
by    O
treatment    O
of    O
cellulose    O
with    O
dimethyl    O
sulfate    O
and    O
ethyl    B-Anesthetic102710766
chloride    I-Anesthetic102710766
in    O
the    O
presence    O
of    O
an    O
alkali    O
.    O

The    O
body    O
was    O
found    O
next    O
to    O
a    O
canister    O
of    O
ethyl    B-Anesthetic102710766
chloride    I-Anesthetic102710766
,    O
but    O
no    O
trace    O
of    O
it    O
or    O
other    O
stimulants    O
or    O
alcohol    O
were    O
found    O
in    O
his    O
blood    O
stream    O
.    O

SN2    O
reaction    O
of    O
a    O
bromide    O
ion    O
with    O
chloroethane    B-Anesthetic102710766
showing    O
the    O
concerted    O
nature    O
of    O
the    O
reaction    O
,    O
the    O
transition    O
state    O
and    O
the    O
predictable    O
stereochemistry    O
through    O
Walden    O
inversion    O
.    O

The    O
preparation    O
of    O
these    O
films    O
occurs    O
with    O
the    O
loss    O
of    O
chloroethane    B-Anesthetic102710766
:    O

S-17092    B-Anesthetic102710766

2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine    B-Anesthetic102710766

He    O
also    O
identified    O
opportunities    O
for    O
new    O
drugs    O
to    O
be    O
used    O
as    O
anesthesia    O
,    O
including    O
isoflurane    O
,    O
sevoflurane    B-Anesthetic102710766
,    O
and    O
desflurane    B-Anesthetic102710766
.    O

Examples    O
include    O
sevoflurane    B-Anesthetic102710766
,    O
desflurane    B-Anesthetic102710766
,    O
enflurane    O
,    O
and    O
isoflurane    O
,    O
all    O
hydrofluorocarbon    O
derivatives    O
.    O

Desflurane    B-Anesthetic102710766
-    O
6.6    O

desflurane    B-Anesthetic102710766

Methoxyflurane    B-Anesthetic102710766
-    O
0.16    O

methoxyflurane    B-Anesthetic102710766

methoxyflurane    B-Anesthetic102710766
(    O
anaesthetic    O
)    O

Methitural    B-Anesthetic102710766
(    O
INN    O
;    O
Neraval    B-Anesthetic102710766
,    O
Thiogenal    B-Anesthetic102710766
)    O
,    O
or    O
methitural    B-Anesthetic102710766
sodium    I-Anesthetic102710766
,    O
also    O
known    O
as    O
methioturiate    B-Anesthetic102710766
,    O
is    O
a    O
barbiturate    O
derivative    O
which    O
was    O
marketed    O
in    O
the    O
1950s    O
in    O
Europe    O
(    O
in    O
Germany    O
and    O
Italy    O
)    O
as    O
an    O
ultra    O
-    O
short    O
-    O
acting    O
intravenous    O
anesthetic    O
.    O

Daclatasvir    O
has    O
been    O
tested    O
in    O
combination    O
regimens    O
with    O
pegylated    O
interferon    O
and    O
ribavirin    O
,    O
as    O
well    O
as    O
with    O
other    O
direct    O
-    O
acting    O
antiviral    O
agents    O
including    O
asunaprevir    B-Anesthetic102710766
and    O
sofosbuvir    O
.    O

It    O
is    O
both    O
the    O
precursor    O
and    O
the    O
chief    O
metabolite    O
of    O
the    O
inhalation    B-Anesthetic102710766
anesthetic    I-Anesthetic102710766
sevoflurane    B-Anesthetic102710766
.    O

He    O
also    O
identified    O
opportunities    O
for    O
new    O
drugs    O
to    O
be    O
used    O
as    O
anesthesia    O
,    O
including    O
isoflurane    O
,    O
sevoflurane    B-Anesthetic102710766
,    O
and    O
desflurane    B-Anesthetic102710766
.    O

It    O
improves    O
post    O
-    O
operative    O
pain    O
relief    O
,    O
is    O
better    O
at    O
inducing    O
sedation    O
at    O
induction    O
,    O
reduces    O
agitated    O
emergence    O
,    O
reduces    O
shivering    O
and    O
post    O
-    O
operative    O
nausea    O
and    O
vomiting    O
and    O
reduces    O
post    O
-    O
operative    O
delirium    O
associated    O
with    O
sevoflurane    B-Anesthetic102710766
anaesthesia    O
.    O

Examples    O
include    O
sevoflurane    B-Anesthetic102710766
,    O
desflurane    B-Anesthetic102710766
,    O
enflurane    O
,    O
and    O
isoflurane    O
,    O
all    O
hydrofluorocarbon    O
derivatives    O
.    O

Sevoflurane    B-Anesthetic102710766
-    O
1.8    O

sevoflurane    B-Anesthetic102710766

prazepam    B-Anesthetic102710766

Benzodiazepines    O
with    O
a    O
half    O
-    O
life    O
of    O
more    O
than    O
24    O
hours    O
include    O
chlordiazepoxide    O
,    O
diazepam    O
,    O
clobazam    O
,    O
clonazepam    O
,    O
chlorazepinic    O
acid    O
,    O
ketazolam    O
,    O
medazepam    O
,    O
nordazepam    O
,    O
and    O
prazepam    B-Anesthetic102710766
.    O

Coprine    B-Anesthetic102710766
(    O
which    O
is    O
an    O
amino    O
acid    O
found    O
in    O
certain    O
coprinoid    O
mushrooms    O
)    O
metabolizes    O
in    O
vivo    O
to    O
1-aminocyclopropanol    O
which    O
causes    O
similar    O
effects    O
as    O
well    O
.    O

However    O
,    O
the    O
fruit    O
bodies    O
are    O
suspected    O
to    O
contain    O
the    O
Antabuse    O
-    O
like    O
chemical    O
coprine    B-Anesthetic102710766
,    O
which    O
causes    O
a    O
poisoning    O
reaction    O
when    O
consumed    O
with    O
alcohol    O
.    O

Other    O
agents    O
which    O
have    O
been    O
shown    O
to    O
reverse    O
chloroquine    O
resistance    O
in    O
malaria    O
are    O
chlorpheniramine    O
,    O
gefitinib    O
,    O
imatinib    O
,    O
tariquidar    O
and    O
zosuquidar    B-Anesthetic102710766
.    O

Romifidine    B-Anesthetic102710766

A-796,260    B-Anesthetic102710766

The    O
Virginia    O
Cooperative    O
Extension    O
recommends    O
Micotil    O
,    O
Nuflor    O
,    O
and    O
Baytril    B-Anesthetic102710766
100    I-Anesthetic102710766
as    O
newer    O
antibiotics    O
that    O
do    O
not    O
need    O
daily    O
dosing    O
,    O
but    O
also    O
notes    O
that    O
Naxcel    O
,    O
Excenel    O
,    O
and    O
Adspec    O
are    O
effective    O
as    O
well    O
.    O

In    O
1998    O
and    O
1999    O
,    O
Chopra    O
,    O
along    O
with    O
two    O
co    O
-    O
workers    O
,    O
Drs    O
.    O
Margaret    O
Haydon    O
and    O
Gerard    O
Lambert    O
,    O
testified    O
to    O
the    O
Canadian    O
Senate    O
"    O
Standing    O
Committee    O
on    O
Agriculture    O
and    O
Forestry    O
"    O
that    O
they    O
were    O
pressured    O
by    O
senior    O
supervisors    O
to    O
approve    O
multiple    O
drugs    O
of    O
questionable    O
safety    O
,    O
including    O
Bovine    O
Growth    O
Hormone    O
(    O
rBST    O
)    O
and    O
Baytril    B-Anesthetic102710766
,    O
which    O
in    O
the    O
words    O
of    O
Chopra    O
,    O
"    O
is    O
even    O
more    O
controversial    O
.    O

Following    O
this    O
,    O
Chopra    O
,    O
Haydon    O
,    O
Lambert    O
and    O
colleague    O
Chris    O
Bassude    O
complained    O
to    O
the    O
Public    O
Service    O
Integrity    O
Officer    O
(    O
PSIO    O
)    O
office    O
,    O
a    O
federal    O
investigative    O
body    O
under    O
the    O
jurisdiction    O
of    O
the    O
Treasury    O
Board    O
of    O
Canada    O
,    O
indicating    O
again    O
that    O
they    O
were    O
pressured    O
by    O
their    O
seniors    O
to    O
pass    O
a    O
number    O
of    O
veterinary    O
drugs    O
,    O
including    O
Tylosin    O
,    O
Revalor    O
H    O
,    O
Synergistin    O
Injectable    O
Suspension    O
,    O
Baytril    B-Anesthetic102710766
,    O
rBST    O
,    O
Carbodex    O
and    O
Eugenol    O
,    O
without    O
proof    O
of    O
human    O
safety    O
.    O

After    O
several    O
failed    O
clinical    O
trials    O
,    O
in    O
2010    O
Dov    O
was    O
acquired    O
by    O
Euthymics    O
Bioscience    O
which    O
intended    O
to    O
continue    O
development    O
of    O
Dov    O
's    O
antidepressant    O
,    O
amitifadine    B-Anesthetic102710766
(    O
DOV    O
21,947    O
,    O
renamed    O
EB-1010    O
)    O
.    O

DOV-216,303    O
,    O
the    O
racemic    O
mixture    O
that    O
included    O
amitifadine    B-Anesthetic102710766
,    O
which    O
was    O
discontinued    O
after    O
the    O
patent    O
covering    O
it    O
expired    O
.    O

Butorphanol    B-Anesthetic102710766

Butorphanol    B-Anesthetic102710766

It    O
is    O
a    O
17-cycloalkylmethyl    O
derivative    O
of    O
morphinan    O
and    O
as    O
such    O
,    O
is    O
closely    O
related    O
structurally    O
to    O
butorphanol    B-Anesthetic102710766
,    O
cyclorphan    O
,    O
oxilorphan    O
,    O
proxorphan    O
,    O
and    O
xorphanol    O
,    O
which    O
act    O
preferentially    O
as    O
κ-opioid    O
receptor    O
agonists    O
and    O
to    O
a    O
lesser    O
extent    O
as    O
μ-opioid    O
receptor    O
partial    O
agonists    O
/    O
antagonists    O
.    O

Butorphanol    B-Anesthetic102710766

A    O
variety    O
of    O
partial    O
agonists    O
or    O
mixed    O
agonists    O
-    O
antagonists    O
of    O
the    O
MOR    O
and    O
KOR    O
are    O
also    O
marketed    O
,    O
and    O
include    O
butorphanol    B-Anesthetic102710766
,    O
levorphanol    O
,    O
nalbuphine    O
,    O
pentazocine    O
,    O
and    O
phenazocine    O
.    O

Other    O
drugs    O
of    O
the    O
partial    O
mu    O
-    O
opioid    O
agonist    O
/    O
antagonist    O
type    O
include    O
meptazinol    O
,    O
buprenorphine    B-Anesthetic102710766
,    O
butorphanol    B-Anesthetic102710766
,    O
phenazocine    O
,    O
nalbuphine    O
,    O
pentazocine    O
,    O
dezocine    O
and    O
its    O
relatives    O
.    O

PHCCC    B-Anesthetic102710766
:    O
PAM    O
of    O
mGluR4    O
,    O
negative    O
allosteric    O
modulator    O
of    O
mGluR1    O
,    O
direct    O
agonist    O
at    O
mGluR6    O

He    O
starts    O
by    O
driving    O
Scully    O
's    O
car    O
to    O
Nutter    O
's    O
Feed    O
Store    O
in    O
a    O
small    O
town    O
near    O
the    O
abductions    O
,    O
as    O
the    O
human    O
remains    O
contain    O
acepromazine    B-Anesthetic102710766
,    O
an    O
animal    O
tranquilizer    O
.    O

Acepromazine    B-Anesthetic102710766
(    O
antipsychotic    O
,    O
secondary    O
mechanism    O
)    O

According    O
to    O
Berdella    O
,    O
he    O
plied    O
Howell    O
with    O
alcohol    O
,    O
Valium    O
and    O
acepromazine    B-Anesthetic102710766
both    O
in    O
his    O
car    O
and    O
at    O
his    O
house    O
until    O
the    O
youth    O
became    O
unconscious    O
.    O

Acepromazine    B-Anesthetic102710766
,    O
veterinary    O
sedative    O

TAC    B-Anesthetic102710766

Cyclopropylmethyl(a-methyl-3,4-methylenedioxyphenethyl)amine    B-Anesthetic102710766

Ptaquiloside    B-Anesthetic102710766
is    O
a    O
norsesquiterpene    O
glucoside    O
produced    O
by    O
bracken    O
ferns    O
(    O
majorly    O
"    O
Pteridium    O
aquilinum    O
"    O
)    O
during    O
metabolism    O
.    O

pazufloxacin    B-Anesthetic102710766
(    O
Pasil    O
,    O
Pazucross    O
)    O

To    O
test    O
its    O
new    O
antibiotic    O
,    O
trovafloxacin    B-Anesthetic102710766
(    O
Trovan    O
)    O
,    O
Pfizer    O
gave    O
100    O
children    O
trovafloxacin    O
,    O
while    O
another    O
100    O
received    O
the    O
gold    O
-    O
standard    O
anti    O
-    O
meningitis    O
treatment    O
,    O
ceftriaxone    O
,    O
a    O
cephalosporin    O
antibiotic    O
.    O

Trovafloxacin    B-Anesthetic102710766
(    O
sold    O
as    O
Trovan    B-Anesthetic102710766
by    O
Pfizer    O
and    O
Turvel    B-Anesthetic102710766
by    O
Laboratorios    O
Almirall    O
)    O
was    O
a    O
broad    O
spectrum    O
antibiotic    O
that    O
inhibits    O
the    O
uncoiling    O
of    O
supercoiled    O
DNA    O
in    O
various    O
bacteria    O
by    O
blocking    O
the    O
activity    O
of    O
DNA    O
gyrase    O
and    O
topoisomerase    O
IV    O
.    O

Cyclopentobarbital    B-Anesthetic102710766

Panadiplon    B-Anesthetic102710766
(    O
U-78875    B-Anesthetic102710766
)    O
is    O
an    O
anxiolytic    O
drug    O
with    O
a    O
novel    O
chemical    O
structure    O
that    O
is    O
not    O
closely    O
related    O
to    O
other    O
drugs    O
of    O
this    O
type    O
.    O

2C-T-8    B-Anesthetic102710766
is    O
a    O
psychedelic    O
phenethylamine    O
of    O
the    O
2C    O
family    O
.    O

propofol    B-Anesthetic102710766
and    O
fospropofol    B-Anesthetic102710766
(    O
anesthetics    O
)    O

DOV-102,677    B-Anesthetic102710766
is    O
a    O
psychoactive    O
drug    O
being    O
developed    O
by    O
Merck    O
and    O
is    O
currently    O
in    O
clinical    O
trials    O
.    O

Pradofloxacin    B-Anesthetic102710766
(    O
trade    O
name    O
Veraflox    B-Anesthetic102710766
)    O
is    O
a    O
3rd    O
generation    O
enhanced    O
spectrum    O
veterinary    O
antibiotic    O
of    O
the    O
fluoroquinolone    O
class    O
.    O

grepafloxacin    B-Anesthetic102710766
(    O
INN    O
)    O

One    O
important    O
acylfulvene    O
,    O
6-hydroxymethylacylfulvene    O
(    O
irofulven    B-Anesthetic102710766
)    O
,    O
has    O
been    O
evaluated    O
for    O
the    O
treatment    O
of    O
a    O
wide    O
assortment    O
of    O
cancers    O
and    O
tumors    O
.    O

Cicloprolol    B-Anesthetic102710766

falintolol    B-Anesthetic102710766
(    O
INN    O
)    O

2C-T-15    B-Anesthetic102710766

This    O
has    O
been    O
used    O
in    O
Tibet    O
as    O
a    O
substitute    O
for    O
'    O
'    O
Tsang    O
-    O
ch'ieh    O
"    O
(    O
transliterated    O
also    O
as    O
Zang    O
Qie    O
)    O
-    O
Anisodus    O
tanguticus    O
,    O
more    O
commonly    O
known    O
in    O
China    O
as    O
"    O
shān    O
làngdàng    O
''    O
(=    O
山莨菪    O
=    O
'    O
mountain    O
henbane    B-Anesthetic102710766
'    O
)    O
.    O

The    O
larvae    O
mainly    O
feed    O
on    O
Convolvulaceae    O
species    O
,    O
including    O
"    O
Calystegia    O
sepium    O
"    O
,    O
"    O
Calystegia    O
spithamaea    O
"    O
,    O
"    O
Calystegia    O
soldanella","Convolvulus    O
arvensis    O
"    O
,    O
"    O
Convolvulus    O
cantabrica    O
"    O
,    O
"    O
Convolvulus    O
floridus    O
"    O
,    O
"    O
Convolvulus    O
prostratus    O
"    O
,    O
"    O
Convolvulus    O
tricolor    O
"    O
,    O
"    O
Ipomoea    O
batatas    O
"    O
,    O
"    O
Ipomoea    O
eriocarpa    O
"    O
and    O
"    O
Ipomoea    O
purpurea    O
"    O
,    O
and    O
also    O
"    O
Atriplex    O
"    O
(    O
including    O
"    O
Atriplex    O
patula    O
"    O
)    O
and    O
"    O
Chenopodium    O
"    O
(    O
including    O
"    O
Chenopodium    O
album    O
"    O
)    O
from    O
the    O
Amaranthaceae    O
family    O
,    O
"    O
Cynara    O
cardunculus    O
"    O
from    O
the    O
Asteraceae    O
family    O
,    O
and    O
"    O
Datura    O
stramonium    O
"    O
and    O
"    O
Hyoscyamus    B-Anesthetic102710766
niger    I-Anesthetic102710766
"    O
from    O
the    O
Solanaceae    O
family    O
.    O

The    O
island    O
has    O
a    O
rich    O
variety    O
of    O
flora    O
,    O
notably    O
motherwort    O
(    O
"    O
Leonurus    O
cardiaca    O
"    O
)    O
,    O
henbane    B-Anesthetic102710766
(    O
"    O
Hyoscyamus    O
niger    O
"    O
)    O
,    O
blue    O
iris    O
(    O
"    O
Iris    O
spuria    O
"    O
)    O
and    O
chickweed    O
.    O

Henbane    B-Anesthetic102710766

"    O
Hyoscyamus    B-Anesthetic102710766
niger    I-Anesthetic102710766
"    O

In    O
1879    O
,    O
Fletcher    O
's    O
Field    O
was    O
identified    O
by    O
the    O
Pharmaceutical    O
Society    O
of    O
Great    O
Britain    O
as    O
a    O
notable    O
source    O
of    O
Hyoscyamus    B-Anesthetic102710766
niger    I-Anesthetic102710766
,    O
a    O
psychoactive    O
plant    O
.    O

"    O
Hyoscyamus    B-Anesthetic102710766
niger    I-Anesthetic102710766
"    O
(    O
henbane    O
)    O

In    O
the    O
19th    O
century    O
,    O
the    O
primary    O
anodynes    O
were    O
opium    O
,    O
henbane    B-Anesthetic102710766
,    O
hemlock    O
,    O
tobacco    O
,    O
nightshade    O
(    O
"    O
stramonium    O
"    O
)    O
,    O
and    O
chloroform    O
.    O

Depending    O
on    O
the    O
type    O
of    O
plants    O
,    O
the    O
maximum    O
concentration    O
is    O
observed    O
in    O
the    O
leaves    O
(    O
black    B-Anesthetic102710766
henbane    I-Anesthetic102710766
)    O
,    O
fruits    O
or    O
seeds    O
(    O
Strychnine    O
tree    O
)    O
,    O
root    O
(    O
"    O
Rauwolfia    O
serpentina    O
"    O
)    O
or    O
bark    O
(    O
cinchona    O
)    O
.    O

Tasimelteon    B-Anesthetic102710766

It    O
is    O
in    O
the    O
same    O
class    O
of    O
melatonin    O
receptor    O
agonists    O
as    O
ramelteon    O
and    O
tasimelteon    B-Anesthetic102710766
.    O

Organophosphates    O
and    O
carbonates    O
can    O
induce    O
a    O
chain    O
of    O
responses    O
leading    O
to    O
neuromuscular    B-Anesthetic102710766
blockage    I-Anesthetic102710766
.    O

Neuromuscular-blocking    B-Anesthetic102710766
drug    I-Anesthetic102710766

Candocuronium    O
iodide    O
(    O
INN    O
,    O
formerly    O
chandonium    O
,    O
HS-310    O
)    O
is    O
an    O
aminosteroid    O
neuromuscular-blocking    B-Anesthetic102710766
drug    I-Anesthetic102710766
or    O
skeletal    O
muscle    O
relaxant    O
in    O
the    O
category    O
of    O
non    O
-    O
depolarizing    O
neuromuscular    O
-    O
blocking    O
drugs    O
.    O

Metocurine    O
is    O
a    O
muscle    O
relaxant    O
through    O
neuromuscular    B-Anesthetic102710766
blockade    I-Anesthetic102710766
.    O

EMG    O
then    O
an    O
acceleromyograph    O
may    O
be    O
used    O
for    O
neuromuscular    O
monitoring    O
in    O
general    O
anesthesia    O
with    O
neuromuscular-blocking    B-Anesthetic102710766
drug    I-Anesthetic102710766
,    O
in    O
order    O
to    O
avoid    O
postoperative    O
residual    O
curarization    O
(    O
PORC    O
)    O
.    O

Anticholinergics    O
are    O
divided    O
into    O
three    O
categories    O
in    O
accordance    O
with    O
their    O
specific    O
targets    O
in    O
the    O
central    O
and    O
peripheral    O
nervous    O
system    O
:    O
antimuscarinic    O
agents    O
,    O
ganglionic    O
blockers    O
,    O
and    O
neuromuscular    B-Anesthetic102710766
blockers    I-Anesthetic102710766
.    O

The    O
site    O
has    O
a    O
long    O
history    O
of    O
research    O
in    O
the    O
area    O
of    O
neuromuscular    B-Anesthetic102710766
blocker    I-Anesthetic102710766
,    O
which    O
are    O
commonly    O
used    O
during    O
surgery    O
,    O
and    O
was    O
responsible    O
for    O
the    O
identification    O
of    O
rocuronium    O
as    O
well    O
as    O
a    O
number    O
of    O
other    O
drugs    O
.    O

Soricidin    O
is    O
a    O
paralytic    B-Anesthetic102710766
oligopeptide    O
found    O
in    O
the    O
venomous    O
saliva    O
of    O
the    O
northern    O
short    O
-    O
tailed    O
shrew    O
(    O
"    O
Blarina    O
brevicauda    O
"    O
)    O
;    O
in    O
the    O
wild    O
,    O
shrews    O
use    O
it    O
to    O
paralyze    O
their    O
prey    O
(    O
typically    O
insects    O
)    O
.    O

"    O
Classic    O
"    O
RSI    O
involves    O
pre    O
-    O
filling    O
the    O
patient    O
's    O
lungs    O
with    O
a    O
high    O
concentration    O
of    O
oxygen    O
gas    O
,    O
followed    O
by    O
applying    O
cricoid    O
pressure    O
,    O
administering    O
rapid    O
-    O
onset    O
sedative    O
or    O
hypnotic    O
and    O
neuromuscular-blocking    B-Anesthetic102710766
drug    I-Anesthetic102710766
that    O
induce    O
prompt    O
unconsciousness    O
and    O
paralysis    O
,    O
inserting    O
an    O
endotracheal    O
tube    O
with    O
minimal    O
delay    O
,    O
and    O
then    O
releasing    O
the    O
cricoid    O
pressure    O
.    O

The    O
neuromuscular    B-Anesthetic102710766
blocking    I-Anesthetic102710766
agents    I-Anesthetic102710766
paralyze    O
all    O
of    O
the    O
skeletal    O
muscles    O
,    O
most    O
notably    O
and    O
importantly    O
in    O
the    O
oropharynx    O
,    O
larynx    O
,    O
and    O
diaphragm    O
.    O

Sedatives    O
,    O
analgesics    O
and    O
paralytic    B-Anesthetic102710766
agent    I-Anesthetic102710766
are    O
often    O
used    O
.    O

bupivacaine    B-Anesthetic102710766

Bupivacaine    B-Anesthetic102710766

A    O
mixture    O
of    O
1    O
part    O
2%    O
lidocaine    B-Anesthetic102710766
with    O
3    O
parts    O
0.5%    O
bupivacaine    B-Anesthetic102710766
(    O
trade    O
name    O
:    O
Marcaine    O
)    O
provides    O
0.5%    O
lidocaine    O
and    O
0.375%    O
bupivacaine    O
.    O

Cardiotoxicity    O
may    O
be    O
caused    O
by    O
chemotherapy    O
treatment    O
,    O
complications    O
from    O
anorexia    O
nervosa    O
,    O
adverse    O
effects    O
of    O
heavy    O
metals    O
intake    O
,    O
or    O
an    O
incorrectly    O
administered    O
drug    O
such    O
as    O
bupivacaine    B-Anesthetic102710766
.    O

This    O
can    O
be    O
completed    O
either    O
by    O
in    O
vivo    O
marcaine    B-Anesthetic102710766
infiltration    O
of    O
muscle    O
tissue    O
that    O
can    O
then    O
be    O
grown    O
in    O
vitro    O
,    O
or    O
have    O
in    O
vitro    O
induction    O
of    O
autologous    O
adipose    O
tissue    O
followed    O
by    O
selection    O
of    O
myogenic    O
stem    O
cells    O
that    O
can    O
be    O
recreated    O
in    O
vivo    O
.    O

A    O
topical    O
anesthetic    O
,    O
usually    O
viscous    O
lidocaine    B-Anesthetic102710766
is    O
instilled    O
into    O
the    O
urethra    O
,    O
and    O
a    O
penile    O
(    O
crown    O
)    O
clamp    O
is    O
applied    O
for    O
at    O
least    O
five    O
minutes    O
,    O
then    O
removed    O
immediately    O
prior    O
to    O
the    O
insertion    O
of    O
a    O
cystoscope    O
equipped    O
with    O
a    O
transurethral    O
injection    O
system    O
containing    O
a    O
local    O
anesthetic    O
(    O
most    O
often    O
2%    O
(    O
plain    O
)    O
lidocaine    B-Anesthetic102710766
,    O
or    O
0.5%    O
(    O
plain    O
)    O
bupivicaine    B-Anesthetic102710766
)    O
.    O

Ropivacaine    O
was    O
developed    O
after    O
bupivacaine    B-Anesthetic102710766
was    O
noted    O
to    O
be    O
associated    O
with    O
cardiac    O
arrest    O
,    O
particularly    O
in    O
pregnant    O
women    O
.    O

As    O
for    O
bupivacaine    B-Anesthetic102710766
,    O
Celepid    O
,    O
a    O
commonly    O
available    O
intravenous    O
lipid    O
emulsion    O
,    O
can    O
be    O
effective    O
in    O
treating    O
severe    O
cardiotoxicity    O
secondary    O
to    O
local    O
anaesthetic    O
overdose    O
in    O
animal    O
experiments    O
and    O
in    O
humans    O
in    O
a    O
process    O
called    O
lipid    O
rescue    O
.    O

In    O
the    O
1940s    O
,    O
two    O
product    O
families    O
were    O
established    O
which    O
were    O
to    O
become    O
quite    O
important    O
to    O
Astra    O
:    O
penicillin    O
and    O
anaesthetics    O
,    O
initially    O
in    O
the    O
form    O
of    O
Xylocain    B-Anesthetic102710766
,    O
which    O
was    O
introduced    O
on    O
the    O
Swedish    O
market    O
in    O
1948    O
.    O

lidocaine    B-Anesthetic102710766
(    O
also    O
known    O
as    O
lignocaine    O
)    O

Tracheal    O
tubes    O
may    O
also    O
be    O
used    O
as    O
a    O
route    O
for    O
administration    O
of    O
certain    O
medications    O
such    O
as    O
salbutamol    O
,    O
atropine    O
,    O
epinephrine    O
,    O
ipratropium    O
,    O
and    O
lidocaine    B-Anesthetic102710766
.    O

Lidocaine    B-Anesthetic102710766

Lidocaine/epinephrine    B-Anesthetic102710766

Although    O
its    O
use    O
has    O
largely    O
been    O
replaced    O
by    O
lidocaine    B-Anesthetic102710766
,    O
it    O
is    O
still    O
in    O
use    O
today    O
,    O
most    O
frequently    O
in    O
dentistry    O
.    O

The    O
pudendal    O
block    O
gets    O
its    O
name    O
because    O
a    O
local    O
anesthetic    O
,    O
such    O
as    O
lidocaine    B-Anesthetic102710766
or    O
chloroprocaine    O
,    O
is    O
injected    O
into    O
the    O
pudendal    O
canal    O
where    O
the    O
pudendal    O
nerve    O
is    O
located    O
.    O

A    O
mixture    O
of    O
1    O
part    O
2%    O
lidocaine    B-Anesthetic102710766
with    O
3    O
parts    O
0.5%    O
bupivacaine    B-Anesthetic102710766
(    O
trade    O
name    O
:    O
Marcaine    O
)    O
provides    O
0.5%    O
lidocaine    O
and    O
0.375%    O
bupivacaine    O
.    O

Local    O
anesthetics    O
such    O
as    O
lidocaine    B-Anesthetic102710766
,    O
pramoxine    B-Anesthetic102710766
,    O
or    O
benzocaine    O
in    O
topical    O
creams    O
or    O
lotions    O

Other    O
drugs    O
used    O
for    O
ventricular    O
arrhythmia    O
include    O
lidocaine    B-Anesthetic102710766
,    O
amiodarone    O
,    O
bretylium    O
,    O
flecainide    O
,    O
procainamide    O
,    O
and    O
mexiletine    O
.    O

In    O
"    O
Macrobrachium    O
americanum    O
"    O
,    O
prawns    O
treated    O
with    O
lignocaine    B-Anesthetic102710766
(    O
a    O
local    O
anaesthetic    O
in    O
mammals    O
)    O
,    O
showed    O
less    O
rubbing    O
,    O
flicking    O
and    O
sheltering    O
than    O
those    O
without    O
the    O
anaesthetic    O
.    O

Intravenous    O
lidocaine    B-Anesthetic102710766
requires    O
more    O
study    O
before    O
it    O
can    O
be    O
recommended    O
for    O
pain    O
.    O

One    O
study    O
concluded    O
that    O
the    O
iontophoretic    O
administration    O
of    O
lidocaine    B-Anesthetic102710766
was    O
safe    O
and    O
effective    O
in    O
providing    O
dermal    O
anesthesia    O
for    O
venipuncture    O
in    O
children    O
6–17    O
years    O
old    O
.    O

The    O
nerves    O
to    O
be    O
ablated    O
are    O
identified    O
through    O
injections    O
of    O
local    O
anesthesia    O
(    O
such    O
as    O
lidocaine    B-Anesthetic102710766
)    O
prior    O
to    O
the    O
RFA    O
procedure    O
.    O

A    O
variety    O
of    O
"    O
topical    O
anaesthetic    O
"    O
creams    O
have    O
been    O
developed    O
,    O
ranging    O
from    O
single    O
agents    O
with    O
good    O
skin    O
penetration    O
,    O
to    O
eutectic    O
mixtures    O
of    O
agents    O
and    O
technologically    O
modern    O
formulations    O
of    O
lignocaine    B-Anesthetic102710766
in    O
microspheres    O
.    O

Lodwig    O
instructed    O
a    O
nurse    O
to    O
bring    O
him    O
some    O
potassium    O
chloride    O
and    O
lignocaine    B-Anesthetic102710766
.    O

Lidocaine    B-Anesthetic102710766
and    O
Novocaine    O
belong    O
to    O
a    O
class    O
of    O
local    O
anesthetics    O
which    O
block    O
sodium    O
ion    O
channels    O
.    O

#    O
Second    O
-    O
line    O
treatments    O
—    O
physical    O
therapy    O
,    O
oral    O
medications    O
(    O
amitriptyline    O
,    O
cimetidine    O
or    O
hydroxyzine    O
,    O
pentosan    O
polysulfate    O
)    O
,    O
bladder    O
instillations    O
(    O
DMSO    O
,    O
heparin    O
,    O
or    O
lidocaine    B-Anesthetic102710766
)    O

A    O
topical    O
anesthetic    O
,    O
usually    O
viscous    O
lidocaine    B-Anesthetic102710766
is    O
instilled    O
into    O
the    O
urethra    O
,    O
and    O
a    O
penile    O
(    O
crown    O
)    O
clamp    O
is    O
applied    O
for    O
at    O
least    O
five    O
minutes    O
,    O
then    O
removed    O
immediately    O
prior    O
to    O
the    O
insertion    O
of    O
a    O
cystoscope    O
equipped    O
with    O
a    O
transurethral    O
injection    O
system    O
containing    O
a    O
local    O
anesthetic    O
(    O
most    O
often    O
2%    O
(    O
plain    O
)    O
lidocaine    B-Anesthetic102710766
,    O
or    O
0.5%    O
(    O
plain    O
)    O
bupivicaine    B-Anesthetic102710766
)    O
.    O

Based    O
on    O
this    O
,    O
the    O
authors    O
concluded    O
that    O
the    O
effect    O
of    O
lidocaine    B-Anesthetic102710766
on    O
peripheral    O
nerves    O
most    O
likely    O
explains    O
why    O
the    O
drug    O
has    O
an    O
effect    O
on    O
pain    O
in    O
Dercum    O
's    O
disease    O
.    O

:*    O
Lidocard    O
(    O
"    O
lidocaine    B-Anesthetic102710766
"    O
)    O

Intravenous    O
lidocaine    B-Anesthetic102710766
can    O
abolish    O
symptoms    O
during    O
its    O
administration    O
,    O
or    O
reduce    O
frequency    O
and    O
duration    O
of    O
attacks    O
.    O

Diphenhydramine    O
and    O
lidocaine    B-Anesthetic102710766
also    O
give    O
blue    O
organic    O
layers    O
.    O

It    O
is    O
a    O
2%    O
lidocaine    B-Anesthetic102710766
,    O
0.01    O
mg    O
/    O
ml    O
epinephrine    O
solution    O
.    O

The    O
medical    O
kit    O
had    O
lidocaine    B-Anesthetic102710766
–    O
a    O
local    O
anaesthetic    O
–    O
but    O
the    O
catheter    O
in    O
the    O
kit    O
was    O
designed    O
only    O
for    O
urinary    O
catheterisation    O
and    O
was    O
too    O
soft    O
for    O
use    O
as    O
a    O
chest    O
tube    O
.    O

Investigators    O
inspected    O
a    O
room    O
he    O
had    O
rented    O
in    O
El    O
Cairo    O
and    O
found    O
newspaper    O
clippings    O
of    O
the    O
murders    O
,    O
syringes    O
,    O
Lidocaine    B-Anesthetic102710766
,    O
and    O
the    O
wristwatch    O
Luis    O
Carlos    O
Gálvez    O
was    O
wearing    O
the    O
day    O
he    O
disappeared    O
.    O

Lidocaine    B-Anesthetic102710766
,    O
an    O
anesthetic    O
,    O
and    O
steroids    O
may    O
be    O
injected    O
into    O
painful    O
joints    O
for    O
longer    O
-    O
term    O
pain    O
relief    O
.    O

Lidocaine    B-Anesthetic102710766
is    O
also    O
theorized    O
to    O
blunt    O
a    O
rise    O
in    O
intracranial    O
pressure    O
during    O
laryngoscopy    O
,    O
although    O
this    O
remains    O
controversial    O
and    O
its    O
use    O
varies    O
greatly    O
.    O

To    O
reduce    O
pain    O
with    O
intramuscular    O
injections    O
,    O
ceftriaxone    O
may    O
be    O
reconstituted    O
with    O
lidocaine    B-Anesthetic102710766
.    O

Class    O
Ib    O
—    O
Sodium    O
channels    O
(    O
lidocaine    B-Anesthetic102710766
,    O
phenytoin    O
,    O
mexiletine    O
,    O
tocainide    O
)    O

Other    O
drugs    O
used    O
for    O
ventricular    O
arrhythmia    O
include    O
lidocaine    B-Anesthetic102710766
,    O
amiodarone    O
,    O
bretylium    O
,    O
flecainide    O
,    O
procainamide    O
,    O
and    O
mexiletine    O
.    O

Lidocaine    B-Anesthetic102710766

The    O
rise    O
of    O
gas    O
anesthesia    O
using    O
nitrous    O
oxide    O
,    O
improved    O
equipment    O
for    O
administering    O
anesthetics    O
and    O
the    O
discovery    O
of    O
hexobarbital    B-Anesthetic102710766
in    O
1932    O
led    O
to    O
the    O
gradual    O
decline    O
of    O
chloroform    O
narcosis    O
.    O

hexobarbital    B-Anesthetic102710766

methoxypropane    B-Anesthetic102710766

Agonists    O
/    O
positive    O
allosteric    O
modulators    O
:    O
alcohol    O
(    O
ethanol    O
)    O
,    O
barbiturates    O
,    O
benzodiazepines    O
,    O
carisoprodol    O
,    O
chloral    O
hydrate    O
,    O
etaqualone    O
,    O
etomidate    O
,    O
glutethimide    O
,    O
kava    O
,    O
methaqualone    O
,    O
muscimol    O
,    O
neuroactive    O
steroids    O
,    O
z    O
-    O
drugs    O
,    O
propofol    B-Anesthetic102710766
,    O
skullcap    O
,    O
valerian    O
,    O
theanine    O
,    O
volatile    B-Anesthetic102710766
/    O
inhaled    B-Anesthetic102710766
anaesthetic    I-Anesthetic102710766
.    O

Volatile    B-Anesthetic102710766
agents    I-Anesthetic102710766
are    O
specially    O
formulated    O
organic    O
liquids    O
that    O
evaporate    O
readily    O
into    O
vapors    O
,    O
and    O
are    O
given    O
by    O
inhalation    O
for    O
induction    O
and/or    O
maintenance    O
of    O
general    O
anesthesia    O
.    O

They    O
are    O
most    O
commonly    O
used    O
by    O
anaesthetists    O
to    O
channel    O
oxygen    O
or    O
anaesthesia    B-Anesthetic102710766
gas    I-Anesthetic102710766
to    O
a    O
patient    O
's    O
lungs    O
during    O
surgery    O
and    O
in    O
the    O
pre    O
-    O
hospital    O
setting    O
(    O
for    O
instance    O
by    O
paramedics    O
and    O
emergency    O
medical    O
technicians    O
)    O
for    O
unconscious    O
patients    O
.    O

It    O
is    O
both    O
the    O
precursor    O
and    O
the    O
chief    O
metabolite    O
of    O
the    O
inhalation    B-Anesthetic102710766
anesthetic    I-Anesthetic102710766
sevoflurane    B-Anesthetic102710766
.    O

He    O
was    O
known    O
for    O
his    O
studies    O
on    O
the    O
uptake    O
and    O
distribution    O
of    O
inhalational    B-Anesthetic102710766
anesthetics    I-Anesthetic102710766
,    O
as    O
well    O
for    O
defining    O
the    O
various    O
stages    O
of    O
general    O
anesthesia    O
.    O

However    O
,    O
halothane    O
has    O
a    O
strong    O
odor    O
(    O
although    O
often    O
defined    O
as    O
"    O
pleasant    O
"    O
by    O
comparison    O
with    O
other    O
anesthetic    B-Anesthetic102710766
gases    I-Anesthetic102710766
)    O
.    O

Inhalational    B-Anesthetic102710766
anaesthetic    I-Anesthetic102710766

Inhalational    B-Anesthetic102710766
anaesthetic    I-Anesthetic102710766

MAC    O
is    O
used    O
to    O
compare    O
the    O
strengths    O
,    O
or    O
potency    O
,    O
of    O
anaesthetic    O
vapours    B-Anesthetic102710766
.    O

buprenorphine    B-Anesthetic102710766

Opioid    O
use    O
disorder    O
can    O
be    O
treated    O
with    O
opioid    O
replacement    O
therapy    O
using    O
methadone    O
or    O
buprenorphine    B-Anesthetic102710766
.    O

Commonly    O
used    O
drugs    O
for    O
ORT    O
are    O
methadone    O
or    O
buprenorphine    B-Anesthetic102710766
which    O
are    O
taken    O
under    O
medical    O
supervision    O
.    O

Substance    O
use    O
disorder    O
treatments    O
include    O
prescription    O
of    O
medications    O
such    O
as    O
acamprosate    O
,    O
buprenorphine    B-Anesthetic102710766
,    O
disulfiram    O
,    O
LAAM    O
,    O
methadone    O
,    O
and    O
naltrexone    O
.    O
,    O
as    O
well    O
as    O
effective    O
psychotherapeutic    O
treatment    O
like    O

Pharmacological    O
treatments    O
for    O
SUD    O
include    O
the    O
use    O
of    O
acamprosate    O
,    O
buprenorphine    B-Anesthetic102710766
,    O
disulfiram    O
,    O
LAAM    O
,    O
methadone    O
,    O
and    O
naltrexone    O
.    O

These    O
include    O
replacement    O
therapies    O
such    O
as    O
buprenorphine    B-Anesthetic102710766
and    O
methadone    O
as    O
well    O
as    O
antagonist    O
medications    O
like    O
disulfiram    O
and    O
naltrexone    O
in    O
either    O
short    O
acting    O
,    O
or    O
the    O
newer    O
long    O
acting    O
form    O
.    O

Methadone    O
and    O
buprenorphine    B-Anesthetic102710766
are    O
sometimes    O
used    O
to    O
treat    O
opiate    O
addiction    O
.    O

A    O
2011    O
review    O
of    O
studies    O
suggested    O
that    O
naltrexone    O
,    O
when    O
taken    O
by    O
mouth    O
,    O
was    O
not    O
superior    O
to    O
placebo    O
or    O
to    O
no    O
medication    O
,    O
nor    O
was    O
it    O
superior    O
to    O
benzodiazepine    O
or    O
buprenorphine    B-Anesthetic102710766
.    O

The    O
experts    O
pointed    O
out    O
that    O
Vivitrol    O
's    O
competitors    O
,    O
buprenorphine    B-Anesthetic102710766
and    O
methadone    O
,    O
are    O
"    O
less    O
expensive    O
"    O
,    O
"    O
more    O
widely    O
used    O
"    O
and    O
have    O
been    O
"    O
rigorously    O
studied    O
"    O
.    O

A    O
course    O
of    O
low    O
-    O
dose    O
naltrexone    O
is    O
thus    O
often    O
used    O
as    O
the    O
final    O
step    O
in    O
the    O
treatment    O
of    O
opioid    O
addiction    O
after    O
the    O
patient    O
has    O
been    O
weaned    O
off    O
the    O
substitute    O
agonist    O
such    O
as    O
methadone    O
or    O
buprenorphine    B-Anesthetic102710766
,    O
in    O
order    O
to    O
restore    O
homeostasis    O
and    O
minimize    O
the    O
risk    O
of    O
post    O
acute    O
withdrawal    O
syndrome    O
once    O
the    O
maintenance    O
agonist    O
has    O
been    O
withdrawn    O
.    O

Buprenorphine    B-Anesthetic102710766
and    O
dezocine    O
are    O
partial    O
agonists    O
of    O
the    O
MOR    O
but    O
antagonists    O
of    O
the    O
KOR    O
.    O

Synthesis    O
of    O
morphine    O
-    O
like    O
alkaloids    O
in    O
chemistry    O
describes    O
the    O
total    O
synthesis    O
of    O
the    O
natural    O
morphinan    O
class    O
of    O
alkaloids    O
that    O
includes    O
codeine    O
,    O
morphine    O
,    O
oripavine    O
,    O
and    O
thebaine    O
and    O
the    O
closely    O
related    O
semisynthetic    O
analogs    O
buprenorphine    B-Anesthetic102710766
,    O
hydrocodone    O
,    O
isocodeine    O
,    O
naltrexone    O
,    O
naloxone    O
,    O
nalbuphine    O
,    O
and    O
oxycodone    O
.    O

Other    O
drugs    O
of    O
the    O
partial    O
mu    O
-    O
opioid    O
agonist    O
/    O
antagonist    O
type    O
include    O
meptazinol    O
,    O
buprenorphine    B-Anesthetic102710766
,    O
butorphanol    B-Anesthetic102710766
,    O
phenazocine    O
,    O
nalbuphine    O
,    O
pentazocine    O
,    O
dezocine    O
and    O
its    O
relatives    O
.    O

Buprenorphine    B-Anesthetic102710766
is    O
a    O
partial    O
agonist    O
of    O
the    O
μ-opioid    O
receptor    O
,    O
and    O
tramadol    O
is    O
a    O
serotonin    O
norepinephrine    O
reuptake    O
inhibitor    O
(    O
SNRI    O
)    O
with    O
weak    O
μ-opioid    O
receptor    O
agonist    O
properties    O
.    O

Several    O
commonly    O
used    O
opioid    O
drugs    O
including    O
etorphine    O
and    O
buprenorphine    B-Anesthetic102710766
have    O
been    O
demonstrated    O
to    O
bind    O
to    O
nociceptin    O
receptors    O
,    O
but    O
this    O
binding    O
is    O
relatively    O
insignificant    O
compared    O
to    O
their    O
activity    O
at    O
other    O
opioid    O
receptors    O
in    O
the    O
acute    O
setting    O
(    O
however    O
the    O
non    O
-    O
analgesic    O
NOPr    O
antagonist    O
SB-612,111    O
was    O
demonstrated    O
to    O
potentiate    O
the    O
therapeutic    O
benefits    O
of    O
morphine    O
)    O
.    O

Buprenorphine    B-Anesthetic102710766
(    O
partial    O
agonist    O
,    O
not    O
selective    O
for    O
NOP    O
,    O
also    O
partial    O
agonist    O
of    O
µ-opioid    O
and    O
δ-opioid    O
receptors    O
,    O
and    O
competitive    O
antagonist    O
of    O
κ-opioid    O
receptors    O
)    O

Buprenorphine    B-Anesthetic102710766

buprenorphine    B-Anesthetic102710766
(    O
semisynthetic    O
opioid    O
)    O

1866    O
–    O
Karl    O
of    O
Hohenzollern    O
-    O
Sigmaringen    O
is    O
crowned    O
the    O
Ruling    B-Anesthetic102710766
Prince    I-Anesthetic102710766
of    O
the    O
United    O
Principalities    O
of    O
Romania    O
.    O

Medetomidine    B-Anesthetic102710766

Chloroform    O
could    O
also    O
be    O
mixed    O
with    O
other    O
anesthetic    O
agents    O
such    O
as    O
ether    O
to    O
make    O
C.E.    O
mixture    O
,    O
or    O
ether    O
and    O
alcohol    O
to    O
make    O
A.C.E.    B-Anesthetic102710766
mixture    I-Anesthetic102710766
.    O

"    O
Bichloride    O
of    O
methylene    O
"    O
(    O
30%    O
methanol    O
and    O
70%    O
chloroform    O
)    O
,    O
a    O
variant    O
of    O
the    O
old    O
anesthetic    O
A.C.E.    B-Anesthetic102710766
mixture    I-Anesthetic102710766
.    O

The    O
antidote    O
for    O
an    O
overdose    O
of    O
diazepam    O
(    O
or    O
any    O
other    O
benzodiazepine    O
)    O
is    O
flumazenil    B-Anesthetic102710766
(    O
Anexate    O
)    O
.    O

Flumazenil    B-Anesthetic102710766
is    O
being    O
studied    O
as    O
a    O
potential    O
treatment    O
to    O
reduce    O
withdrawal    O
symptoms    O
.    O

Flumazenil    B-Anesthetic102710766
has    O
been    O
found    O
to    O
stimulate    O
the    O
reversal    O
of    O
tolerance    O
and    O
the    O
normalization    O
of    O
receptor    O
function    O
.    O

:    O
Flumazenil    B-Anesthetic102710766
was    O
found    O
to    O
be    O
more    O
effective    O
than    O
placebo    O
in    O
reducing    O
feelings    O
of    O
hostility    O
and    O
aggression    O
in    O
patients    O
who    O
had    O
been    O
free    O
of    O
benzodiazepines    O
for    O
4    O
-    O
266    O
weeks    O
.    O

In    O
2007    O
,    O
Hoffmann    O
–    O
La    O
Roche    O
the    O
makers    O
of    O
flumazenil    O
,    O
acknowledged    O
the    O
existence    O
of    O
protracted    O
benzodiazepine    O
withdrawal    O
syndromes    O
,    O
but    O
did    O
not    O
recommended    O
flumazenil    B-Anesthetic102710766
to    O
treat    O
the    O
condition    O
.    O

There    O
is    O
no    O
known    O
cure    O
for    O
protracted    O
benzodiazepine    O
withdrawal    O
syndrome    O
except    O
time    O
,    O
however    O
,    O
the    O
medication    O
flumazenil    B-Anesthetic102710766
was    O
found    O
to    O
be    O
more    O
effective    O
than    O
placebo    O
in    O
reducing    O
feelings    O
of    O
hostility    O
and    O
aggression    O
in    O
patients    O
who    O
had    O
been    O
free    O
of    O
benzodiazepines    O
for    O
4–266    O
weeks    O
.    O

Direct    O
binding    O
to    O
the    O
benzodiazepine    O
/    O
flumazenil    B-Anesthetic102710766
binding    O
site    O
of    O
the    O
GABAA    O
receptor    O
does    O
not    O
occur    O
with    O
kavain    O
enantiomers    O
.    O

Flumazenil    B-Anesthetic102710766
was    O
found    O
to    O
be    O
more    O
effective    O
than    O
placebo    O
in    O
reducing    O
feelings    O
of    O
hostility    O
and    O
aggression    O
in    O
patients    O
who    O
had    O
been    O
free    O
of    O
benzodiazepines    O
for    O
4–266    O
weeks    O
.    O

Cetacaine    B-Anesthetic102710766
is    O
an    O
anesthetic    O
that    O
contains    O
the    O
active    O
ingredients    O
of    O
Benzocaine    O
at    O
14%    O
,    O
Butamben    O
at    O
2%    O
,    O
and    O
Tetracaine    O
Hydrochloride    O
at    O
2%    O
.    O

The    O
lowest    O
doses    O
of    O
ketamine    O
and    O
tiletamine    B-Anesthetic102710766
that    O
produced    O
neurotoxic    O
changes    O
visible    O
by    O
light    O
microscope    O
4    O
hours    O
post    O
dose    O
were    O
40    O
(    O
mg    O
/    O
kg    O
sc    O
)    O
and    O
10    O
(    O
mg    O
/    O
kg    O
sc    O
)    O
,    O
respectively    O
.    O

Dogs    O
and    O
cats    O
commonly    O
receive    O
thiopental    O
(    O
no    O
longer    O
allowed    O
in    O
the    O
UK    O
)    O
,    O
ketamine    O
with    O
diazepam    O
,    O
tiletamine    B-Anesthetic102710766
with    O
zolazepam    O
(    O
usually    O
just    O
in    O
cats    O
)    O
,    O
and/or    O
propofol    B-Anesthetic102710766
.    O

Substances    O
with    O
dissociative    O
properties    O
include    O
ketamine    O
,    O
nitrous    O
oxide    O
,    O
alcohol    O
,    O
tiletamine    B-Anesthetic102710766
,    O
amphetamine    O
,    O
dextromethorphan    O
,    O
MK-801    O
,    O
PCP    O
,    O
methoxetamine    O
,    O
salvia    O
,    O
muscimol    O
,    O
atropine    O
,    O
and    O
ibogaine    O
.    O

Pramocaine    B-Anesthetic102710766
(    O
INN    O
and    O
BAN    O
,    O
also    O
known    O
as    O
pramoxine    B-Anesthetic102710766
or    O
pramoxine    B-Anesthetic102710766
HCI    I-Anesthetic102710766
)    O
is    O
a    O
topical    O
anesthetic    O
discovered    O
at    O
Abbott    O
Laboratories    O
in    O
1953    O
and    O
used    O
as    O
an    O
antipruritic    O
.    O

Local    O
anesthetics    O
such    O
as    O
lidocaine    B-Anesthetic102710766
,    O
pramoxine    B-Anesthetic102710766
,    O
or    O
benzocaine    O
in    O
topical    O
creams    O
or    O
lotions    O

Remikiren    B-Anesthetic102710766
,    O
a    O
second    O
-    O
generation    O
renin    O
inhibitor    O
.    O

Sparfloxacin    B-Anesthetic102710766

Other    O
organic    O
compounds    O
have    O
the    O
formula    O
C4H8    O
,    O
namely    O
cyclobutane    O
and    O
methylcyclopropane    B-Anesthetic102710766
,    O
but    O
are    O
not    O
alkenes    O
and    O
do    O
not    O
fall    O
under    O
the    O
name    O
"    O
butene    O
"    O
.    O

Naltrexone    O
can    O
be    O
described    O
as    O
a    O
substituted    O
oxymorphone    O
–    O
here    O
the    O
tertiary    O
amine    O
methyl    O
-    O
substituent    O
is    O
replaced    O
with    O
methylcyclopropane    B-Anesthetic102710766
.    O

Anileridine    B-Anesthetic102710766

Anileridine    B-Anesthetic102710766
,    O
an    O
analgesic    O

MEK    O
inhibitors    O
(    O
trametinib    B-Anesthetic102710766
,    O
MEK162    O
)    O
are    O
used    O
in    O
experiments    O
,    O
often    O
in    O
combination    O
with    O
BRAF    O
inhibitors    O
to    O
treat    O
melanoma    O

Trametinib    B-Anesthetic102710766
(    O
Mekinist    O
)    O

Octriptyline    B-Anesthetic102710766

In    O
2014    O
those    O
in    O
clinical    O
trials    O
included    O
:    O
LY2801653    O
,    O
MP-470    O
(    O
Amuvatinib    O
)    O
,    O
SKI-606    O
(    O
Bosutinib    O
)    O
,    O
MGCD    O
265    O
,    O
ASP2215    O
,    O
XL184    O
(    O
Cabozantinib    B-Anesthetic102710766
)    O
,    O
GSK1363089/XL880    O
(    O
Foretinib    B-Anesthetic102710766
)    O
,    O
SGI-7079    O
,    O
and    O
R428    O
(    O
BGB324    O
)    O
.    O

Cabozantinib    B-Anesthetic102710766
:    O
Drugs    O
from    O
the    O
MPR2    O
inhibitor    O
(    O
Multidrug    O
resistance    O
-    O
associated    O
protein    O
2    O
inhibitors    O
)    O
family    O
such    O
as    O
abacavir    O
could    O
increase    O
the    O
serum    O
concentration    O
of    O
Cabozantinib    O
.    O

Bicifadine    B-Anesthetic102710766
,    O
a    O
triple    O
-    O
uptake    O
inhibitor    O
for    O
pain    O
,    O
licensed    O
from    O
Wyeth    O
in    O
1998    O
,    O

As    O
such    O
the    O
formation    O
of    O
cyclopropane    O
rings    O
,    O
generally    O
referred    O
to    O
as    O
cyclopropanation    B-Anesthetic102710766
,    O
is    O
an    O
active    O
area    O
of    O
chemical    O
research    O
.    O

In    O
this    O
system    O
,    O
the    O
standard    O
Diels    O
-    O
Alder    O
reaction    O
a    O
(    O
4    O
+    O
2)cycloaddition    O
,    O
the    O
1,3-dipolar    O
cycloaddition    O
is    O
a    O
(    O
3    O
+    O
2)cycloaddition    O
and    O
cyclopropanation    B-Anesthetic102710766
of    O
a    O
carbene    O
with    O
an    O
alkene    O
a    O
(    O
2    O
+    O
1)cycloaddition    O
.    O

The    O
thermally    O
-    O
initiated    O
HDDA    O
reaction    O
has    O
been    O
shown    O
to    O
tolerate    O
esters    O
,    O
ketones    O
,    O
protected    O
amides    O
,    O
ethers    O
,    O
protected    O
amines    O
,    O
aryl    O
halides    O
,    O
alkyl    O
halides    O
,    O
alkenes    O
,    O
and    O
cyclopropanes    B-Anesthetic102710766
.    O

Chrysanthemic    O
acid    O
is    O
produced    O
industrially    O
in    O
a    O
cyclopropanation    B-Anesthetic102710766
reaction    O
of    O
a    O
diene    O
as    O
a    O
mixture    O
of    O
cis-    O
and    O
trans    O
isomers    O
,    O
followed    O
by    O
hydrolysis    O
of    O
the    O
ester    O
:    O

One    O
reaction    O
variation    O
is    O
cyclopropanation    B-Anesthetic102710766
to    O
a    O
compound    O
class    O
called    O
"    O
ivyanes    O
"    O
with    O
a    O
reported    O
synthesis    O
in    O
a    O
Simmons–Smith    B-Anesthetic102710766
reaction    I-Anesthetic102710766
(    O
diethyl    O
zinc    O
/    O
trifluoroacetic    O
acid    O
)    O
of    O
the    O
first    O
6    O
members    O
.    O

Besifloxacin    B-Anesthetic102710766
(    O
INN    O
/    O
USAN    O
)    O
is    O
a    O
fourth    O
-    O
generation    O
fluoroquinolone    O
antibiotic    O
.    O

Trimecaine    B-Anesthetic102710766

Detomidine    B-Anesthetic102710766
,    O
etc    O
.    O

Detomidine    B-Anesthetic102710766


